ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL
31 Mai 2019 - 9:15AM
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage
oncology and immunology focused biopharma company, today
announced that it has amended its license agreement with CSL
Limited (CSL) so that ASLAN has full global rights to develop,
manufacture and commercialise ASLAN004 in all indications. The
amended agreement replaces the licensing agreement ASLAN and CSL
signed in May 2014.
Dr Carl Firth, Chief Executive Officer of ASLAN
Pharmaceuticals, said: “We are very excited by the
recent data we have generated on ASLAN004 and we believe that it
has the potential to be a best-in-class treatment for atopic
dermatitis and other inflammatory indications with a differentiated
profile. The amendment of our agreement with CSL is an important
achievement in our strategy to gain greater commercial control and
retain more value from our pipeline programs. We look forward to
reporting further data on ASLAN004 in atopic dermatitis and
investigating its potential in other inflammatory indications.”
Under the terms of the amended agreement, ASLAN will make a
first payment of US$30 million to CSL upon commencement of a phase
3 study of ASLAN004. CSL is also eligible to receive up to US$95
million of regulatory milestones, US$655 million of sales
milestones and tiered royalties on net sales between mid-single
digits and 10%. Under the terms of the original agreement, ASLAN
was responsible for the development of ASLAN004 through to
proof-of-concept and the identification of a partner to complete
phase 3 development and commercialisation. CSL was eligible to
receive between 40% and 50% of all ASLAN004 revenues, including
proceeds from out-licensing agreements.
ASLAN004 is a fully human monoclonal antibody that targets the
IL-13 receptor α1 subunit, or IL-13Rα1. By targeting IL-13Rα1,
ASLAN004 potently inhibits signalling of both interleukin 4 (IL-4)
and interleukin 13 (IL-13), which are central to triggering
symptoms of allergy in atopic dermatitis. ASLAN is currently
conducting a phase 1 clinical trial in healthy volunteers
investigating ASLAN004 as a treatment for atopic dermatitis.
Recently announced data from the first part of the study
demonstrated that ASLAN004 was safe and well tolerated at all doses
when administered intravenously. Analysis of downstream mediators
including phosphorylation of STAT6, a critical mediator of allergic
inflammation, demonstrated complete inhibition within one hour of
dosing, which was then maintained for more than 29 days. ASLAN
expects to report data from the second part of the study, testing a
subcutaneous formulation, shortly and intends to initiate a
multiple ascending dose study in moderate to severe atopic
dermatitis patients in the second half of 2019.
Atopic dermatitis is the most common dermatological disease,
affecting over 200 million patients worldwide1, characterized by
red inflamed skin and severe daytime and night-time itching, which
can severely impact patients’ quality of life. Up to one-third of
adult atopic dermatitis patients are considered moderate-to-severe,
for which currently available therapeutics are limited and
management is challenging in the majority of cases.
Media and IR contacts
Emma ThompsonSpurwing CommunicationsTel: +65 6571
2021Email: ASLAN@spurwingcomms.com |
Robert UhlWestwicke PartnersTel: +1 858 356
5932Email: robert.uhl@westwicke.com |
About ASLAN004
ASLAN004 is a fully human monoclonal antibody that targets the
IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a
best-in-class therapy. By targeting IL-13Rα1, ASLAN004 potently
inhibits signalling of both interleukin 4, or IL-4, and interleukin
13, or IL-13. IL-4 and IL-13 are central to triggering symptoms of
allergy in atopic dermatitis, such as redness and itching of the
skin, as well as asthma symptoms such as shortness of breath,
exacerbations of disease, wheezing and coughing.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a
clinical-stage oncology and immunology focused biopharma company
targeting cancers that are both highly prevalent in Asia and orphan
indications in the United States and Europe. Led by a senior
management team with extensive experience in global and regional
development and commercialisation, ASLAN is headquartered in
Singapore and has offices in Taiwan and China. ASLAN’s clinical
portfolio is comprised of three product candidates which target
validated growth pathways applied to new patient segments, novel
immune checkpoints and novel cancer metabolic pathways. ASLAN’s
partners include Array BioPharma, Bristol-Myers Squibb, Almirall
and CSL. For additional information please visit
www.aslanpharma.com.
Forward looking statements
This release contains forward-looking statements. These
statements are based on the current beliefs and expectations of the
management of ASLAN Pharmaceuticals Limited and/or its affiliates
(the "Company"). These forward-looking statements may include, but
are not limited to, statements regarding the Company’s plans for
developing ASLAN004 as a potential best-in-class therapy for atopic
dermatitis and other inflammatory indications, the Company’s
strategy to gain greater commercial control and retain value from
its pipeline programs, the Company’s expectations as to the timing
of reporting data from the second part of its Phase 1 clinical
trial of ASLAN004, and the Company’s plans and timing to initiate a
multiple ascending dose study . These forward-looking statements
are based on management's current assumptions and expectations of
future events and trends, which affect or may affect the Company’s
business, strategy, operations or financial performance, and
inherently involve significant known and unknown risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the risk factors described in the
Company’s US Securities and Exchange Commission filings and reports
(Commission File No. 001-38475), including the Company’s Annual
Report on Form 20-F for the year ended December 31, 2018 filed with
the US Securities and Exchange Commission on April 29,
2019.
All statements other than statements of historical fact are
forward-looking statements. The words “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan,” or the negative of those terms, and
similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. Estimates, projections and other
forward-looking statements speak only as of the date they were
made, and, except to the extent required by law, the Company
undertakes no obligation to update or review any estimate,
projection or forward-looking statement.
____________________________________1 Nutten, S. 2015. Atopic
dermatitis: global epidemiology and risk factors
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024